DelveInsight's, "Bispecific antibody Competitive landscape, 2025," report provides comprehensive insights about 180+ companies and 250+ drugs in Bispecific antibody Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Request a sample and discover the recent advances in Bispecific Antibody Drugs @ https://www.delveinsight.com/sample-request/bispecific-antibody-competitive-landscape
Key Takeaways from the Bispecific Antibody Competitive Landscape Report
- On February 19, 2026- Merus B.V. initiated a phase 1/2 open-label multicenter study will be performed with an initial dose escalation part to determine the MTD and/or the RP2D of MCLA-129 in monotherapy or in combination in patients with NSCLC, HNSCC, GC/GEJ, ESCC, or other solid tumors and who are treatment naïve or have progressed after receiving prior therapy for advanced/metastatic disease.
- On February 18, 2026- Regeneron Pharmaceuticals announced a phase 2 study is to see how safe, tolerable, and effective the study drug is on its own and in combination with other anti-cancer drugs (bevacizumab, cemiplimab, fianlimab and a standard chemotherapy drug, pegylated liposomal doxorubicin [PLD]), referred to as "combination drugs'.
- On February 18, 2026- AstraZeneca initiated a Phase II study evaluating the preliminary efficacy and safety of Volrustomig or Rilvegostomig as monotherapy (MONO) and/or in combination with anticancer agents (COMBO) in participants with advanced hepatobiliary cancer (e.g., HCC, BTC, etc.).
- On February 13, 2026- Janssen Pharmaceutical K.K. conducted a phase 1/2 study is to evaluate the safety and tolerability in Japanese participants with relapsed or refractory multiple myeloma (RRMM) at the recommended Phase 2 dose (RP2D) identified in Study 64007957MMY1001 (NCT03145181) in Phase 1 part and to evaluate the efficacy of teclistamab at RP2D for Japanese participants in Phase 2 part.
- On February 13, 2026- Genmab announced a phase 1b/2 trial is to determine the recommended phase 2 dose (RP2D) and the maximum tolerated dose (MTD; if reached) as well as establish the safety profile of epcoritamab monotherapy and epcoritamab + venetoclax in participants with R/R CLL.
- DelveInsight's Bispecific Antibody report depicts a robust space with 180+ active players working to develop 250+ pipeline therapies for Bispecific Antibody treatment.
- The leading companies working in the Bispecific Antibody Competitive landscape include Janssen, Amgen, Akeso, Zymeworks, Roche, IGM Biosciences, MacroGenics, Provention Bio, Jiangsu Alphamab Biopharmaceuticals, Sichuan Baili Pharmaceutical, Regeneron Pharmaceuticals, Boehringer Ingelheim, and others.
- Promising Bispecific Antibody Therapies in the various stages of development include SI-B003, AK104, Bevacizumab, Paclitaxel, AK112, LY3434172, CDX-527, Etoposide, Carboplatin, and others.
The Bispecific Antibody competitive landscape report provides an in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing, and acquisition - deal values trends. The sub-segmentation is described in the Bispecific Antibody report which provides company-company collaboration (licensing/partnering), company academic collaboration, and acquisition analysis in tabulated form.
Bispecific Antibody Overview
Immunoglobulins (antibodies [Abs]) are major protein components of the adaptive immune system, directed against foreign compounds and infectious agents. The IgG molecule consists of two light and two heavy chains connected by disulfide bonds; IgG is a monomer with a molecular weight of 146-160 kDa. Antigen-binding centers of Abs are formed by hypervariable regions of heavy and light chains. In the classical point of view, the Ab molecule contains two identical antigen-binding sites (two HL fragments) and is monospecific and bivalent.
Find out more about Bispecific Antibody Analytical Perspective: In-depth Commercial Assessment @ Bispecific Antibody Collaboration Analysis by Companies
Bispecific Antibody Competitive Landscape
The Bispecific Antibody competitive landscape report comprises of comparative assessment of Companies (by therapy, development stage, and technology).
Bispecific Antibody Report Assessment
- Bispecific Antibody Company Analysis
- Bispecific Antibody Therapeutic Assessment
- Bispecific Antibody Pipeline Assessment
- Inactive drugs assessment
- Bispecific Antibody Unmet Needs
Learn more about the emerging Bispecific Antibody Competitive Landscape @ Bispecific Antibody Market Drivers and Barriers, Unmet Needs
Scope of the Bispecific Antibody Report
- Coverage- Global
- Bispecific Antibody Therapeutics Assessment: Product Type, Stage and Product Type, Route of Administration, Molecule Type
- Bispecific Antibody Companies- Janssen, Amgen, Akeso, Zymeworks, Roche, IGM Biosciences, MacroGenics, Provention Bio, Jiangsu Alphamab Biopharmaceuticals, Sichuan Baili Pharmaceutical, Regeneron Pharmaceuticals, Boehringer Ingelheim, and others.
- Bispecific Antibody Therapies- SI-B003, AK104, Bevacizumab, Paclitaxel, AK112, LY3434172, CDX-527, Etoposide, Carboplatin, and others.
Dive deep into rich insights for new drugs for Bispecific Antibody Product Developmental Activities, Visit @ Bispecific Antibody Research and Development Activities
Table of Content
- Introduction
- Executive Summary
- Bispecific antibody: Overview
- Bispecific Antibody -Analytical Perspective: In-depth Commercial Assessment
- Competitive Landscape
- Therapeutic Assessment
- Bispecific antibody: Company and Product Profiles (Marketed Therapies)
- Janssen
- Amivantamab
- Bispecific antibody: Company and Product Profiles (Pipeline Therapies)
- Late Stage Products (Phase III)
- Akeso
- Ivonescimab
- Drug profiles in the detailed report.....
- Mid Stage Products (Phase II)
- IGM Biosciences
- Imvotamab
- Drug profiles in the detailed report.....
- Early Stage Products (Phase I)
- MacroGenics
- MGD024
- Drug profiles in the detailed report.....
- Preclinical and Discovery Stage Products
- Company Name
- Product Name
- Drug profiles in the detailed report.....
- Inactive Products
- Bispecific antibody- Unmet needs
- Bispecific antibody - Market drivers and barriers
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/bispecific-antibody-competitive-landscape